Suzuki Haruna, Oshino Tomohiro, Hagio Kanako, Takeshita Takashi, Yamashita Hiroko
Dept. of Breast Surgery, Hokkaido University Hospital.
Gan To Kagaku Ryoho. 2020 Sep;47(9):1351-1353.
The characteristic adverse events of olaparib, a PARP inhibitor, are nausea, vomiting, and anemia, and interstitial pneumonia is rarely reported. We report a case of interstitial pneumonia following the treatment of a metastatic breast cancer with olaparib. The patient was a 34-year-old woman. In March 2018, she was diagnosed with stage Ⅳ breast cancer(multiple lung metastases). She was treated with epirubicin and cyclophosphamide followed by paclitaxel. In November 2018, brain and spinal cord metastases were detected, and she was treated with radiation. In December 2018, a BRCA1 deleterious mutation was confirmed, and treatment with olaparib was initiated. Six weeks later, olaparib was discontinued due to anemia; it also caused interstitial pneumonia. The interstitial pneumonia resolved following multidisciplinary treatment during hospitalization. Subsequently, she was treated with cyclophosphamide/methotrexate/fluorouracil. It is necessary to consider interstitial pneumonia as an adverse effect of olaparib.
聚（腺苷酸）核糖聚合酶（PARP）抑制剂奥拉帕利的典型不良事件为恶心、呕吐和贫血，间质性肺炎鲜有报道。我们报告1例用奥拉帕利治疗转移性乳腺癌后发生间质性肺炎的病例。患者为一名34岁女性。2018年3月，她被诊断为Ⅳ期乳腺癌（多发肺转移）。她接受了表柔比星和环磷酰胺治疗，随后接受紫杉醇治疗。2018年11月，检测到脑和脊髓转移，她接受了放射治疗。2018年12月，确认存在BRCA1有害突变，开始用奥拉帕利治疗。六周后，因贫血停用奥拉帕利；它还引起了间质性肺炎。住院期间经多学科治疗，间质性肺炎得以缓解。随后，她接受了环磷酰胺/甲氨蝶呤/氟尿嘧啶治疗。有必要将间质性肺炎视为奥拉帕利的一种不良反应。
